First-line Therapy for metastatic hormone-sensitive Prostate Cancer (mHSPC) Randomized, double-blind Phase III Study of Pembrolizumab (MK-3475) plus Enzalutamide plus ADT compared with Placebo Plus Enzalutamide Plus ADT in Participants with metastatic hormone-sensitive Prostate Cancer (mHSPC) (KEYNOTE-991) - AP 108/19 of the AUO

被引：0
|
作者：
Rexer, H. [1 ]
Retz, M. [2 ]
Hammerer, P. [3 ]
机构：
[1] AUO Geschaftsstelle, Schwarz, Germany
[2] Tech Univ Munich, Urol Klin & Poliklin, Klinikum rdl, Munich, Germany
[3] Deutsch Krebsgesellschaft eV, Organgrp Arbeitsgemeinschaft Urol, Berlin, Germany
来源：
UROLOGE | 2021年 / 60卷 / 07期
关键词：
D O I：
10.1007/s00120-021-01570-0
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：987 / 988
页数：2
相关论文
共 50 条
  • [21] Correlation of PSA and survival in metastatic hormone-sensitive prostate cancer treated with rezvilutamide plus ADT in the CHART trial
    Bian, Xiaojie
    Gu, Weijie
    Zhang, Xuepei
    Xie, Liping
    Wang, Shaogang
    Shi, Benkang
    Sun, Ting
    Wei, Shaozhong
    Weng, Zhiliang
    Xia, Shujie
    Han, Bangmin
    Xu, Zhuoqun
    Xing, Jinchun
    Zhang, Dahong
    Xu, Danfeng
    Du, Chuanjun
    He, Chaohong
    Wang, Qilin
    Yang, Xinfeng
    Lian, Jianpo
    Wang, Wenliang
    Ye, Dingwei
    MED, 2025, 6 (02):
  • [22] Prevalence of DNA damage repair (DDR) alterations in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving enzalutamide (ENZA) or placebo (PBO) plus androgen deprivation therapy (ADT): ARCHES post hoc analysis.
    Azad, Arun
    Iguchi, Taro
    Alekseev, Boris
    Shore, Neal D.
    Sugg, Jennifer
    Haas, Gabriel P.
    Wozniak, Michele
    O'Brien, Thomas
    Laird, Douglas
    Stenzl, Arnulf
    Armstrong, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [23] Abiraterone plus prednisone in patients with newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC)
    Miller, Kurt
    AKTUELLE UROLOGIE, 2019, 50 (06) : 625 - 628
  • [24] Post hoc analysis of East Asian subpopulation in arches, a phase 3 study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (MHSPC)
    Iguchi, Taro
    Pu, Yeong-Shiau
    Kimura, Go
    Byun, Seok-Soo
    Ha, Hong Koo
    Hong, Jun Hyuk
    Li, Jian-Ri
    Sugg, Jennifer
    Haas, Gabriel P.
    Stenzl, Arnulf
    Armstrong, Andrew J.
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 : 96 - 97
  • [25] SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients (pts) with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) (NCT01809691).
    Agarwal, Neeraj
    Tangen, Catherine
    Hussain, Maha H. A.
    Gupta, Shilpa
    Plets, Melissa
    Lara, Primo
    Harzstark, Andrea
    Twardowski, Przemyslaw
    Paller, Channing Judith
    Zylla, Dylan M.
    Zibelman, Matthew R.
    Levine, Ellis Glenn
    Roth, Bruce J.
    Goldkorn, Amir
    Vaena, Daniel A.
    Kohli, Manish
    Crispino, Tony
    Vogelzang, Nicholas J.
    Thompson, Ian Murchie
    Quinn, David I.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [26] CYCLONE 3: A phase III, randomized, double-blind, placebocontrolled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer (mHSPC)
    Mckay, R. R.
    Agarwal, N.
    Matsubara, N.
    Rodriguez, J. M. Piulats
    Smith, M. R.
    Todenhofer, T.
    Zhang, T.
    Balar, A. V.
    Schaverien, C.
    Sherwood, S.
    Johnston, E.
    Lithio, A.
    Nacerddine, K.
    Sweeney, C. J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1195 - S1196
  • [27] LIBERTAS: A degendered and transgender-inclusive phase 3 study of apalutamide (APA) plus intermittent vs continuous androgen deprivation therapy (ADT) in participants (pts) with metastatic hormone-sensitive prostate cancer (mHSPC)
    Azad, Arun
    Musto, Clark
    Netanel, Shir
    Zhang, Tian
    Rathkopf, Dana E.
    Badillo, Marco Antonio
    Dong, Qiang
    Morgans, Alicia K.
    Runcie, Karie
    Dos Santos, Alex
    Bhaumik, Amitabha
    Mundle, Suneel
    McCarthy, Sharon
    Lopez-Gitlitz, Angela Mennicke
    Batavia, Ashita S.
    Sanchez, Daniel P.
    Wildgust, Mark A.
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
    Armstrong, Andrew J.
    Szmulewitz, Russell Z.
    Petrylak, Daniel P.
    Holzbeierlein, Jeffrey
    Villers, Arnauld
    Azad, Arun
    Alcaraz, Antonio
    Alekseev, Boris
    Iguchi, Taro
    Shore, Neal D.
    Rosbrook, Brad
    Sugg, Jennifer
    Baron, Benoit
    Chen, Lucy
    Stenzl, Arnulf
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (32) : 2974 - +
  • [29] Efficacy and safety of enzalutamide plus androgen deprivation therapy vs placebo plus androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: the ongoing ARCHES trial
    Stenzl, A.
    Krivoshik, A.
    Baron, B.
    Hirmand, M.
    Armstrong, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [30] Clinical outcomes and safety of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) in patients aged < 75 and ≥ 75 years: ARCHES post hoc analysis.
    Szmulewitz, Russell Zelig
    Holzbeierlein, Jeffrey
    Azad, Arun
    Iguchi, Taro
    Villers, Arnauld
    Alcaraz, Antonio
    Alekseev, Boris
    Shore, Neal D.
    Rosbrook, Brad
    Zohren, Fabian
    Ma, Jie
    Haas, Gabriel P.
    Gomez-Veiga, Francisco
    Stenzl, Arnulf
    Armstrong, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345